Immunotherapy shows benefits for hospitalised COVID-19 patients
Apogenix’s asunercept demonstrates efficacy in Phase II trial for the treatment of hospitalised COVID-19 patients.
List view / Grid view
Apogenix’s asunercept demonstrates efficacy in Phase II trial for the treatment of hospitalised COVID-19 patients.
15 June 2016 | By Victoria White, Digital Content Producer
A Phase I trial showed that APG101 was well tolerated. In addition, the study showed that APG101 efficiently stimulates erythropoiesis in these patients...